Market Overview:
The leishmaniasis treatment market consists of drugs used for treating leishmaniasis, which is caused by Leishmania protozoa. The drugs recommended as first-line treatments are antimonial compounds such as sodium stibogluconate and meglumine antimoniate. These drugs are very effective but require long-term intravenous administration and are associated with toxicity.
Market key trends:
One of the key trends in the leishmaniasis treatment market is the development of combination therapies for enhanced efficacy. Combination therapies using existing drugs along with new chemical entities can help reduce treatment duration and increase efficacy while lowering toxicity. For instance, a clinical trial is underway to evaluate a 3-drug combination therapy of miltefosine, paromomycin, and sodium stibogluconate for the treatment of visceral leishmaniasis. The combination aims to reduce treatment duration, prevent relapses, and lower toxicity of individual drugs.
Segment Analysis
The global leishmaniasis treatment market is dominated by the visceral leishmaniasis sub-segment which holds nearly 60% of the market share. This is because visceral leishmaniasis, also known as kala-azar, is the most severe form of leishmaniasis with a high fatality rate if left untreated. The disease spreads to internal organs like liver, spleen if not treated on time.
Key Takeaways
The global Leishmaniasis Treatment Market Demand is expected to witness high growth, exhibiting a CAGR of 4.4% over the forecast period, due to increasing prevalence of leishmaniasis worldwide, growing research and development activities for novel treatment drugs, and rising government initiatives to control the disease.
Regional analysis
By region, Asia Pacific accounts for the largest share in the global leishmaniasis treatment market owing to the high prevalence of the disease across India, Nepal, Bangladesh and other Southeast Asian countries. Increased investment by key market players and various awareness & control programs by governments in these regions are driving market growth. North America is expected to grow at the fastest rate during the forecast period due to high funding for research activities.
Key players
Key players operating in the leishmaniasis treatment market are Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical. Among these, Sanofi dominates the market with its injectable drug Amphotericin B. Gland Pharma and Sanofi are focusing on developing low-cost treatment options to increase penetration in developing countries.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it